Overcome complex development challenges in your Zika vaccine trial

As infectious diseases such as the Zika virus continue to threaten public health, it’s essential that you, as a vaccine developer, work closely with a laboratory partner in order to avoid challenges along the drug development continuum.

Download our new insight brief, Zika Vaccine Research: Complex Steps toward a Critical Need, to discover 5 key questions that should be asked prior to beginning your vaccine study, concerning:
  • Vaccine immunogenicity
  • Efficacy
  • Exposure to related viruses
Q2 Solutions has a geographic footprint, scientific and therapeutic expertise, and deep understanding of global, regional and local requirements for vaccine and anti-infective clinical trials. Learn more about how we can be your trusted partner for vaccine development.
Keeping Up with the Flu: Advances in seasonal influenza vaccine development

Q2 Solutions Anti-infective and Vaccine Development Services

Assays to drive success in anti-infective and vaccine development

Extensive expertise for vaccine assay development and diagnostics

Read More